IDEXX Laboratories, Inc. $IDXX Stock Position Decreased by Employees Retirement System of Texas

Employees Retirement System of Texas cut its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 21.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,406 shares of the company’s stock after selling 2,276 shares during the quarter. Employees Retirement System of Texas’ holdings in IDEXX Laboratories were worth $5,687,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Virtus Advisers LLC bought a new stake in shares of IDEXX Laboratories during the 3rd quarter worth $26,000. Park Place Capital Corp bought a new stake in shares of IDEXX Laboratories during the 4th quarter worth $29,000. WealthCollab LLC bought a new stake in shares of IDEXX Laboratories during the 2nd quarter worth $30,000. Greykasell Wealth Strategies Inc. bought a new stake in shares of IDEXX Laboratories during the 3rd quarter worth $35,000. Finally, Caitong International Asset Management Co. Ltd bought a new stake in shares of IDEXX Laboratories during the 3rd quarter worth $36,000. 87.84% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on IDXX shares. Stifel Nicolaus reduced their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. Barclays cut their target price on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. BTIG Research decreased their target price on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. Piper Sandler decreased their target price on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research report on Monday, February 9th. Finally, Weiss Ratings cut IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Seven equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $751.00.

Insider Transactions at IDEXX Laboratories

In related news, EVP Nimrata Hunt sold 1,758 shares of IDEXX Laboratories stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $634.57, for a total transaction of $1,115,574.06. Following the completion of the sale, the executive vice president owned 18,141 shares of the company’s stock, valued at approximately $11,511,734.37. This trade represents a 8.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.79% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock opened at $550.99 on Thursday. The stock has a market cap of $43.46 billion, a PE ratio of 40.57, a price-to-earnings-growth ratio of 3.24 and a beta of 1.58. The business has a fifty day simple moving average of $565.23 and a 200-day simple moving average of $638.69. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a 12 month low of $504.56 and a 12 month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. The firm had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The business’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter last year, the firm earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.